Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Extension Study in sJIA
NCT00144612Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2004
- Primary completion
- Jun 2005
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Percentage of patients showing 30% improvement in the JIA core set compared with before the first infusion of the investigational product, Incidence and severity of adverse events and adverse reactions and 1 more. Started Jul 2004; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT00144612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144612.